Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin–bound paclitaxel in patients with advanced solid tumors
Maysa Abu‐Khalaf(Sidney Kimmel Cancer Center), Lyndsay N. Harris(National Institutes of Health)
Cited by 14
Related Papers
Molecular Definition of Breast Tumor Heterogeneity
|Cancer Cell|2007|1.4k
Effect of Capivasertib in Patients With an <i>AKT1 E17K</i>-Mutated Tumor
|JAMA Oncology|2020|106
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
|npj Precision Oncology|2022|42